Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R-Reference-Cited by-同舟云学术

Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R

Published:2024-06 Issue:6 Volume:9 Page:103464
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Filippi A.R.^ORCID,Bar J.^ORCID,Chouaid C.,Christoph D.C.^ORCID,Field J.K.,Fietkau R.,Garassino M.C.,Garrido P.^ORCID,Haakensen V.D.^ORCID,Kao S.,Markman B.,McDonald F.,Mornex F.,Moskovitz M.,Peters S.,Sibille A.,Siva S.,van den Heuvel M.,Vercauter P.,Anand S.,Chander P.,Licour M.,de Lima A.R.,Qiao Y.,Girard N.

Funder

AstraZeneca

Publisher

Elsevier BV

Reference29 articles.

1. Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival;Casal-Mourino;Transl Lung Cancer Res,2021

2. Lung cancer in Spain: information from the Thoracic Tumors Registry (TTR study);Provencio;Transl Lung Cancer Res,2019

3. Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004-2007;Walters;Thorax,2013

4. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC;Antonia;N Engl J Med,2018

5. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer;Antonia;N Engl J Med,2017

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. What Does N2 Lymph Node Involvement Mean for Patients with Non-Small Cell Lung Cancer (NSCLC)?—A Review of Implications for Diagnosis and Treatment;Cancers;2024-07-26

2. Association Between PD-L1 Score and the Outcomes of Consolidation Durvalumab in a Large Nationwide Series of Patients With Stage III NSCLC Treated With Chemoradiotherapy;Clinical Lung Cancer;2024-07